Internet Archive Scholar

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update

Charles L. Loprinzi, Christina Lacchetti, Jonathan Bleeker, Guido Cavaletti, Cynthia Chauhan, Daniel L. Hertz, Mark R. Kelley, Antoinette Lavino, Maryam B. Lustberg, Judith A. Paice, Bryan P. Schneider, Ellen M. Lavoie Smith (+4 others)
2020 Journal of Clinical Oncology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (2.6 MB)
https://web.archive.org/web/20220519034627/https://scholarworks.iupui.edu/bitstream/handle/1805/27436/Loprinzi2020Prevention.pdf;jsessionid=A4A1C0391C44A7119AC40CCDA4BDF238?sequence=1

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN
more » ... addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited. Additional information is available at www.asco.org/survivorship-guidelines .
doi:10.1200/jco.20.01399 pmid:32663120 fatcat:6asotlihorekfgvmq5orjyy6vq
Citation

Charles L. Loprinzi, Christina Lacchetti, Jonathan Bleeker, Guido Cavaletti, Cynthia Chauhan, Daniel L. Hertz, Mark R. Kelley, Antoinette Lavino, Maryam B. Lustberg, Judith A. Paice, Bryan P. Schneider, Ellen M. Lavoie Smith, Mary Lou Smith, Thomas J. Smith, Nina Wagner-Johnston, Dawn L. Hershman. "Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update." Journal of Clinical Oncology 38.28 (2020) JCO.20.01399